Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142818 · ClinicalTrials.gov registry record · Phase 2
Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence
A Phase 2 study, sponsored by Kyle Kampman.
- Completed
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
NCT00142818 is a Phase 2 study that has completed, run by Kyle Kampman. The registered enrollment target is 164 participants.
The verdict
NCT00142818, a Phase 2 study, has completed, sponsored by Kyle Kampman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
Study Summary
Modafinil is a medication that may enhance mood and increase energy in cocaine addicts, which may be useful in preventing cocaine relapse. Naltrexone is a medication that is currently used to treat drug and alcohol addiction. A combination of these two medications may be beneficial in reducing drug and alcohol use in individuals undergoing substance abuse treatment. The purpose of this study is to evaluate the effectiveness of modafinil and naltrexone, alone and in combination, at reducing drug and alcohol use in individuals addicted to cocaine and alcohol.
Interventions
- DRUG Placebo
- DRUG Modafinil
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2006-02 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142818
The ClinicalTrials.gov registry entry for NCT00142818 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyle Kampman, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00142818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142818 about?
NCT00142818 is a clinical study titled "Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence". Modafinil is a medication that may enhance mood and increase energy in cocaine addicts, which may be useful in preventing cocaine relapse. Naltrexone is a medication that is currently used to treat drug and alcohol addiction. A combination of these two medications may be beneficial in reducing drug ...
What is the current status of trial NCT00142818?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2006-02. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00142818?
The interventions under investigation include: Placebo (DRUG), Modafinil (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT00142818?
This trial is sponsored by Kyle Kampman, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.